KRAS and ovarian cancer: In addition, of 8 patients (colorectal cancer, n = 3; NSCLC, n = 1; endometrial cancer, n = 1; breast cancer, n = 1; ovarian cancer, n = 1; melanoma, n = 1) with KRAS G12 or G13 mutation in cfDNA, but not in FFPE tumor samples, 2 patients had KRAS Q61 mutations in FFPE.